ANAB · AnaptysBio Inc
United States · RS rating 49 · As of 2026-10-14
| Price | 46.67 USD |
|---|---|
| 1-day change | +2.4% |
| RS rating (overall / 1M / 3M / 12M) | 49 / 16 / 26 / 96 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 45 / 30 / 57 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +203.8% |
| Sales growth Q/Q | +41.8% |
| Distance from 52-week high | +33.1% |
| Market cap (USD) | $1.5B |